Zinbryta (daclizumab beta) - Important Safety Information from Biogen as approved by the HPRA (August 2018)

Notice type: 3rd Party Publications

Date: 09/08/2018

 

Problem Or Issue:
Important Safety Information communication from Biogen on Zinbryta (Daclizumab beta): Cases of immune-mediated encephalitis, including anti-NMDA receptor encephalitis, reported several months after discontinuation of treatment.



« Back